Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iscalimab - Novartis

Drug Profile

Iscalimab - Novartis

Alternative Names: CFZ-533; NVP-CFZ533; OM11-62-MF

Latest Information Update: 29 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; XOMA
  • Developer Novartis
  • Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Monoclonal antibodies; Urologics
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graves' disease; Hidradenitis suppurativa; Liver transplant rejection; Lupus nephritis; Myasthenia gravis; Renal transplant rejection; Sjogren's syndrome; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 29 Jul 2022 Novartis plans to submit first regulatory application for Hidradenitis suppurativa in or after 2026 (Novartis pipeline, February 2022)
  • 08 Feb 2022 Phase-II clinical trials in Hidradenitis suppurativa in Switzerland (IV) (Novartis pipeline, February 2022)
  • 08 Feb 2022 Phase-II clinical trials in Hidradenitis suppurativa in Switzerland (SC) (Novartis pipeline, February 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top